Updates are available Correction dated 2025-03-31
Click to view Correction: https://doi.org/10.1038/s41573-025-01190-9
-
Authors
Rieder, Florian https://orcid.org/0000-0002-9087-1568
Nagy, Laura E. https://orcid.org/0000-0002-0580-2809
Maher, Toby M. https://orcid.org/0000-0001-7192-9149
Distler, Jörg H. W.
Kramann, Rafael
Hinz, Boris https://orcid.org/0000-0002-0526-393X
Prunotto, Marco https://orcid.org/0000-0002-0203-0129
- License Information
-
More Information
Article History
Accepted: 10 February 2025
First Online: 18 March 2025
Change Date: 31 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41573-025-01190-9
Competing interests
: F.R. is on the advisory board of or consultant to Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, AstraZeneca, Bausch & Lomb, Boehringer-Ingelheim, Celgene/BMS, Celltrion, CDISC, Celsius, Cowen, Eugit, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Janssen, Koutif, Mestag, Metacrine, Mirum, Mopac, Morphic, Myka Labs, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, Trix Bio, UCB, Ysios and 89Bio. J.H.W.D. has consultancy relationships with and/or is part of the speaker or advisory board of AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer-Ingelheim, Calliditas Therapeutics, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche and UCB. J.H.W.D. has received research funding from Anamar, Argenx, ARXX, BMS, Bayer Pharma, Boehringer-Ingelheim, Cantargia, Celgene, CSL Behring, Galapagos, GSK, Inventiva, Kiniksa, Lassen, Sanofi-Aventis, RedX and UCB. J.H.W.D. is CEO of 4D Science and Scientific Lead of FibroCure. R.K. is founder and shareholder of Sequantrix GmbH and has grants from Travere Therapeutics, Galapagos, Chugai, AskBio and Novo Nordisk and is a consultant for Bayer, Roche, Chugai, Pfizer, Novo Nordisk, Hybridize Therapeutics and Gruenenthal. T.M.M., via his institution, has received industry-academic funding from AstraZeneca and GlaxoSmithKline R&D; and consultancy or speaker fees from AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, CSL Behring, Fibrogen, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Merck, Pliant, Pfizer, Qureight, Roche, Sanofi-Aventis, Structure Therapeutics, Trevi and Veracyte. M.P. is an employee of Medicxi Ventures. L.E.N. and B.H. declare no competing interests.
